Journal international de médecine physique et de réadaptation
Libre accès

Abstrait

Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome

Shin J Oh*

Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.